Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide.
Articolo
Data di Pubblicazione:
2008
Abstract:
The higher relaxivity of gadobenate dimeglumine compared with gadodiamide is potentially advantageous for contrast-enhanced brain MR imaging. This study intraindividually compared 0.1-mmol/kg doses of these agents for qualitative and quantitative lesion enhancement.Adult patients with suggested or known brain lesions underwent 2 identical MR imaging examinations at 1.5T, one with gadobenate dimeglumine and the other with gadodiamide. The agents were administered in randomized order separated by 3-14 days. Imaging sequences and postinjection acquisition timing were identical for the 2 examinations. Three blinded readers evaluated images qualitatively for diagnostic information (lesion extent, delineation, morphology, enhancement, and global preference) and quantitatively for contrast-to-noise ratio (CNR).One hundred thirteen of 138 enrolled patients successfully underwent both examinations. Final diagnoses were intra-axial tumor, metastasis, extra-axial tumor, or other (47, 27, 18, and 21 subjects, respectively). Readers 1, 2, and 3 demonstrated global preference for gadobenate dimeglumine in 63 (55.8\%), 77 (68.1\%), and 73 (64.6\%) patients, respectively, compared with 3, 2, and 3 patients for gadodiamide (P < .0001, all readers). Highly significant (P < .0001, all readers) preference for gadobenate dimeglumine was demonstrated for all qualitative end points and for CNR (increases of 23.3\%-34.7\% and 42.4\%-48.9\% [spin-echo and gradient-refocused echo sequences, respectively] for gadobenate dimeglumine compared with gadodiamide). Inter-reader agreement was good for all evaluations (kappa = 0.47-0.69). Significant preference for gadobenate dimeglumine was demonstrated for all lesion subgroup analyses.Significantly greater diagnostic information and lesion enhancement are achieved on brain MR imaging with 0.1-mmol/kg gadobenate dimeglumine compared with gadodiamide at an equivalent dose.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Adolescent, Adult, Aged, Aged; 80 and over, Brain Neoplasms; diagnosis/secondary, Brain; pathology, Contrast Media, Cross-Over Studies, Female, Gadolinium DTPA; diagnostic use, Humans, Image Enhancement, Magnetic Resonance Imaging, Male, Meglumine; analogs /&/ derivatives/diagnostic use, Middle Aged, Observer Variation, Organometallic Compounds; diagnostic use, Sensitivity and Specificity, Young Adult
Elenco autori:
H. A., Rowley; G., Scialfa; P. y., Gao; J. A., Maldjian; D., Hassell; M. J., Kuhn; F. J., Wippold; M., Gallucci; B. C., Bowen; I. M., Schmalfuss; J., Ruscalleda; Bastianello, Stefano; C., Colosimo
Link alla scheda completa:
Pubblicato in: